Novo Rebrands as Novo, Lilly Wins FDA Nod, GE HealthCare Nears $1B Sofie Deal

Eli Lilly's updated fair value estimate has shifted from US$1,297.31 to US$1,325.39, with revenue growth moving from 13.98% to 14.17%, net profit margin from 41.26% to 42.01%, and future P/E from 28.66x to 28.85x, while the discount rate held at 7.24%. The revision sits alongside analyst price targets that often exceed US$900, with a cluster between US$1,300 and US$1,600, as firms including Citi, BMO Capital, RBC Capital, UBS, Morgan Stanley, Bernstein, Truist, Cantor Fitzgerald, BofA, Leerink and Berenberg raised targets into a range stretching from around US$1,135 to US$1,600. Guggenheim lifted its target to US$1,284, incorporating updated prescription and pricing assumptions and the reinstatement of Zepbound on the CVS formulary, while HSBC kept a Reduce rating even after raising its target to US$940, citing elevated sector multiples. The U.S. FDA granted full approval for Eli Lilly's Inluriyo in combination with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy, based on Phase 3 EMBER-3 data showing the combination doubled median progression-free survival versus Inluriyo alone. Eli Lilly also plans to present data on Mounjaro, Zepbound, Foundayo, retatrutide and eloraTZP at the European Association for the Study of Diabetes 2026 meeting in Milan, and Berenberg upgraded the stock citing weight-loss drug growth prospects, a pipeline described through 2030, and around US$60b committed to more than 25 business development deals this year, including acquisitions in sleep and cancer.

The analyst fair value estimate for Iovance Biotherapeutics has been raised from US$9.33 to US$10.00 per share, with recent price targets clustering in the US$10 to US$15 range. Barclays, TD Cowen and Mizuho have all lifted their price targets, with the upper end of recent moves reaching US$15, citing Amtagvi revenue trends, margin progression and the potential impact of upcoming data such as IOV-LUN-202. UBS pointed to Amtagvi revenue of US$91m and a 56% gross margin in Q2, supported by manufacturing efficiency and ATC performance, though it kept a Neutral rating and flagged that a 74% post Q2 rally has already reflected much of the near term upside. Barclays cited its physician survey and sees durability as a key differentiator for lifileucel in second line lung cancer ahead of the IOV-LUN-202 data in Q4, which it views as an important potential catalyst. The updated model also shows the projected net profit margin moving from 7.99% to about 9.50% and the future P/E multiple adjusting from 83.56x to about 75.55x.